Table 3.
Mean score baselinea | Mean score follow-upa | Deterio-ration | No change | Improved | P valueb | ||
---|---|---|---|---|---|---|---|
Frequency of preferred substancec (n = 120) | VA (71) | 2.7 | 1.5 | 4 (5 %) | 24 (34 %) | 43 (61 %) | <0.001 |
CA (49) | 2.8 | 2.2 | 2 (4 %) | 29 (59 %) | 18 (37 %) | <0.001 | |
Cannabisd (n = 49) | VA (28) | 2.7 | 1.5 | 3 (11 %) | 8 (28 %) | 17 (61 %) | <0.001 |
CA (21) | 2.6 | 1.5 | 2 (9 %) | 6 (28 %) | 13 (62 %) | 0.006 | |
Amphetamined (n = 43) | VA (24) | 2.8 | 1.2 | 0 (0 %) | 6 (25 %) | 18 (75 %) | <0.001 |
CA (19) | 2.5 | 1.7 | 2 (10 %) | 7 (37 %) | 10 (53 %) | 0.026 |
aThe ordinal ASI scale (frequency of use in the last 6 months) was defined as follows: 0 = never used; 1 = sometimes, but less than 2–3 times a month; 2 = 1–3 days a week; 3 = everyday use)
b P value from Wilcoxon signed-rank test
cPreferred substance according to the ASI interview
dSub-analyses of specific preferred drug if more than 40 patients reported preference for this substance